From: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis
 | 0.03 mg (N = 7) | 0.1 mg (N = 6) | 0.3 mg (N = 6) | 1 mg (N = 6) | Placebo (N = 8) |
---|---|---|---|---|---|
Number of Patients with at least one AE | 7 (100%) | 5 (83.3%) | 5 (83.3%) | 6 (100%) | 7 (87.5%) |
Number of Patients with no AE | 0 (0%) | 1 (16.7%) | 1 (16.7%) | 0 (0%) | 1 (12.5%) |
Arthralagia | 4 (57.1%) | 1 (16.7%) | 5 (83.3%) | 5 (83.3%) | 6 (75%) |
Nasopharyngitis | 2 (28.6%) | 2 (33.3%) | 1 (16.7%) | 0 (0%) | 1 (12.5%) |
Upper Respiratory Tract Infection | 1 (14.3%) | 0 (0%) | 3 (50%) | 1 (16.7%) | 1 (12.5%) |
Headache | 1 (14.3%) | 2 (33.3%) | 2 (33.3%) | 0 (0%) | 1 (12.5%) |
Influenza | 0 (0%) | 2 (33.3%) | 0 (0%) | 0 (0%) | 2 (25%) |
Joint Stiffness | 2 (28.6%) | 1 (16.7%) | 1 (16.7%) | 0 (0%) | 1 (12.5%) |
Joint Swelling | 2 (28.6%) | 0 (0%) | 0 (0%) | 1 (16.7%) | 0 (0%) |
Lymphadenopathy | 0 (0%) | 1 (16.7%) | 0 (0%) | 1 (16.7%) | 0 (0%) |
Injection Site Bruising | 0 (0%) | 2 (33.3%) | 0 (0%) | 0 (0%) | 0 (0%) |
Injection Site Pain | 1 (14.3%) | 0 (0%) | 0 (0%) | 4 (66.7%) | 1 (12.5%) |
Injection Site Mass | 0 (0%) | 1 (16.7%) | 0 (0%) | 1 (16.7%) | 0 (0%) |
Injection Site Swelling | 1 (14.3%) | 0 (0%) | 1 (16.7%) | 1 (16.7%) | 0 (0%) |